Search results for "platelet"

showing 10 items of 786 documents

Mucosal healing following PRP (Platelet-Rich Plasma) application in post-extraction socket in patients treated with aminobisphosphonates

2014

Settore MED/28 - Malattie Odontostomatologichemucosal healing PRP Platelet-Rich Plasma aminobisphosphonates surgery extraction
researchProduct

Clinical effectiveness of platelet concentrates for periodontal regeneration

2016

Settore MED/28 - Malattie Odontostomatologicheperiodontal regeneration platelet concentrate
researchProduct

Platelet count and MPV as predictive markers of atherosclerosis in familial Mediterranean fever

2017

Familial Mediterranean Fever (FMF) is an auto inflammatory syndrome, characterized by recurrent febrile episodes, arthritis, oral aphthous stomatitis, rash, serositis, abdominal and thoracic pain. Longterm outcome is conventionally linked to the severity of the recurrent attacks and to the risk of systemic amyloidosis. However recent studies highlighted the role of chronic inflammatory diseases in the insurance of atherosclerosis. Risk factors for atherosclerosis are also recently identified in a higher medium platelet volume (MPV).

Settore MED/38 - Pediatria Generale E SpecialisticaFamilial Mediterranean Fever medium platelet volume atherosclerosis
researchProduct

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluat…

2017

Background: Few data are available on the virological and clinical outcomes of advanced liver disease patients retreated after first-line DAA failure. Aim: To evaluate DAA failure incidence and the retreatment clinical impact in patients treated in the advanced liver disease stage. Methods: Data on HCV genotype, liver disease severity, and first and second line DAA regimens were prospectively collected in consecutive patients who reached the 12-week post-treatment and retreatment evaluations from January 2015 to December 2016 in 23 of the PITER network centers. Results: Among 3,830 patients with advanced fibrosis (F3) or cirrhosis, 139 (3.6%) failed to achieve SVR. Genotype 3, bilirubin lev…

SimeprevirMaleGenetics and Molecular Biology (all)HepacivirusPediatricsGastroenterologyBiochemistry0302 clinical medicineAnimal Cells80 and overBileMedicinePublic and Occupational HealthProspective Studieslcsh:ScienceAged 80 and overAdult; Aged; Aged 80 and over; Antiviral Agents; Drug Therapy Combination; Female; Hepatitis C; Humans; Incidence; Liver Diseases; Male; Middle Aged; Prospective Studies; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Liver DiseaseIncidenceLiver DiseasesChild HealthBloodCirrhosisPhysical SciencesRegression Analysis030211 gastroenterology & hepatologyDrug Therapy CombinationCellular TypesStatistics (Mathematics)Humanmedicine.medical_specialtyGastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesDrug TherapyHumansStatistical MethodsAgedBlood CellsBiochemistry Genetics and Molecular Biology (all)Flaviviruseslcsh:ROrganismsBiology and Life Sciencesmedicine.diseaseRegimenProspective Studie030104 developmental biologychemistryAgricultural and Biological Sciences (all)lcsh:QMathematicsDevelopmental BiologyRNA viruses0301 basic medicineDAA HCV resistanceSofosbuvirPhysiologylcsh:MedicineLiver diseasechemistry.chemical_compoundMathematical and Statistical TechniquesMedicine and Health SciencesPathology and laboratory medicineMultidisciplinaryHepatitis C virusHepatitis CMedical microbiologyMiddle AgedHepatitis CBody FluidsVirusesCombinationFemaleAnatomyPathogensResearch Articlemedicine.drugPlateletsLedipasvirAdultDaclatasvirSettore MED/12 - GASTROENTEROLOGIAHCV liver diseases Cirrhosis DAA failureResearch and Analysis MethodsInternal medicineAntiviral Agentbusiness.industryViral pathogensBilirubinCell BiologyFibrosisHepatitis virusesMicrobial pathogensSurgeryLiver functionbusiness
researchProduct

Mediterranean Diet and Physical Activity Decrease the Initiation of Cardiovascular Drug Use in High Cardiovascular Risk Individuals: A Cohort Study

2021

Our aim was to assess whether long-term adherence to a Mediterranean diet (MedDiet) and leisure-time physical activity (LTPA) were associated with a lower initiation of cardiovascular drug use. We studied the association between cumulative average of MedDiet adherence and LTPA and the risk of cardiovascular drug initiation in older adults at high cardiovascular risk (PREvención con DIeta MEDiterránea trial participants) non-medicated at baseline: glucose-lowering drugs (n = 4437), antihypertensives (n = 2145), statins (n = 3977), fibrates (n = 6391), antiplatelets (n = 5760), vitamin K antagonists (n = 6877), antianginal drugs (n = 6837), and cardiac glycosides (n = 6954). One-point increas…

StatinMediterranean dietPhysiologymedicine.drug_classClinical Biochemistryphysical activityFibrateantiplatelet drugs030204 cardiovascular system & hematologyPharmacologyLower riskBiochemistryMetabolic equivalentArticlestatinscardiac glycosides03 medical and health sciences0302 clinical medicineMediterranean cookingMediterranean dietCuina mediterràniamedicine030212 general & internal medicinevitamin K epoxide reductase inhibitorsMolecular BiologyCardiac glycosideglucose-lowering drugsbusiness.industrylcsh:RM1-950mediterranean dietCell BiologyVitamin K antagonistPhysical fitnessCardiovascular agentslcsh:Therapeutics. Pharmacologyantihypertensive drugsantianginal drugsfibratesbusinessCohort studymedicine.drugCondició físicaMedicaments cardiovasculars
researchProduct

Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors

2013

Abstract Among the various hypolipidemic drugs, 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (also known as "statins") belong to a heterogeneous class of compounds, sharing an identical hypocholesterolemic effect that develops through direct inhibition of a rate-limiting step in endogenous cholesterol synthesis. Their mechanism of action entails competitive inhibition of HMG-CoA reductase. Several lines of evidence suggest that the pleiotropic effects of statins may also play a role in prevention of venous thrombosis, wherein hypercholesterolemic patients are characterized by enhanced thrombin generation, increased susceptibility to endothelial dysfunction and plate…

Statinmedicine.drug_classHMG-CoA; statins; thrombosisPharmacologyReductaseRisk AssessmentstatinsHyperlipoproteinemia Type IIHMG-CoARisk FactorsmedicineHumansPlateletEndothelial dysfunctionthrombosisHypolipidemic AgentsVenous Thrombosisbiologybusiness.industryC-reactive proteinHematologymedicine.diseaseThrombosisVenous thrombosisHMG-CoA reductasebiology.proteinHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessSeminars in Thrombosis and Hemostasis
researchProduct

Graphene nanoplatelets (GNPs): new preparation methods and their structural characterization

2012

Graphene is one of the allotropes of elemental carbon with a planar monolayer of carbon atoms arranged into a two-dimensional honey-comb lattice [1]. It has demonstrated a variety of intriguing properties as new material for future applications and composite industry [2-3]. In particular the interesting electrical properties candidate the graphene to be an excellent successor to silicon in electronic applications. Since its preparation is rather difficult and complex, graphene nanoplatelets (GNPs) are also intensively studied. GNPs are more easily to obtain, have similar properties and can be used in the same applications [4]. The aim of the current research is the development of new prepar…

TEM graphene nanoplateletsSettore CHIM/02 - Chimica Fisica
researchProduct

Stroke subtypes and their possible implication in stroke prevention drug strategies

2014

Thrombotic strokes can affect large or small arteries in the brain. Drugs to prevent atherosclerosis complication such as thrombotic strokes, should be drugs able to prevent the accumulation of intravascular fat, reduce vascular proliferation, decrease blood pressure levels with the resulting shear stress, reduce platelet aggregation, and possibly partially or totally reverse carotid plaques. Any of the commonly used antihypertensive drugs lower the incidence of stroke, with larger reductions in BP resulting in larger reductions in risk. Experimental and clinical data suggest that reducing the activity of the renin-angiotensin aldosterone system (RAAS) may have beneficial effects beyond the…

TOAST ClassificationDrugmedicine.medical_specialtySettore MED/09 - Medicina Internamedia_common.quotation_subjectBlood PressureStroke subtype preventionInternal medicinemedicineAnimalsHumanscardiovascular diseasesStrokeAntihypertensive AgentsRandomized Controlled Trials as Topicmedia_commonPharmacologyAspirinbusiness.industryDipyridamoleAtherosclerosismedicine.diseaseSurgeryStrokeDipyridamoleClinical trialBlood pressureCardiologyCardiology and Cardiovascular MedicineComplicationbusinessLipohyalinosisPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Emerging Therapies in Immune Thrombocytopenia

2021

Immune thrombocytopenia (ITP) is a rare autoimmune disorder caused by peripheral platelet destruction and inappropriate bone marrow production. The management of ITP is based on the utilization of steroids, intravenous immunoglobulins, rituximab, thrombopoietin receptor agonists (TPO-RAs), immunosuppressants and splenectomy. Recent advances in the understanding of its pathogenesis have opened new fields of therapeutic interventions. The phagocytosis of platelets by splenic macrophages could be inhibited by spleen tyrosine kinase (Syk) or Bruton tyrosine kinase (BTK) inhibitors. The clearance of antiplatelet antibodies could be accelerated by blocking the neonatal Fc receptor (FcRn), while n…

TPO-RAlcsh:MedicineSykReview03 medical and health sciencesClassical complement pathway0302 clinical medicinehemic and lymphatic diseasesMedicineBruton's tyrosine kinasePlateletB celldesialylationbiologybusiness.industrylcsh:RBTK inhibitorAutoantibodyGeneral MedicineFcRnmedicine.anatomical_structureimmune thrombocytopeniaSyk inhibitor030220 oncology & carcinogenesisImmunologybiology.proteinRituximabAntibodybusiness030215 immunologymedicine.drugJournal of Clinical Medicine
researchProduct

Comparison of GTR, T-PRF and open-flap debridement in the treatment of intrabony defects with endo-perio lesions : a randomized controlled trial

2019

Background Titanium- prepared platelet rich fibrin (T-PRF) is an autologous hemo-component with a high concentration of platelets that also incorporates leukocytes, and growth factors into the dense fibrin matrix and can be used as a healing biomaterial. This study assesses the adjunctive use of T-PRF in intrabony defects (IBDs) with open flap debridement (OFD) in comparison with guided tissue regeneration (GTR) as a gold standard and OFD alone as a control. Material and Methods A total of 45 patients (15 per group) were randomized as either T-PRF (test group), GTR (test group), or OFD alone (control group) sites. Probing depth (PD), clinical attachment level (CAL), and IBD were recorded. T…

Test groupmedicine.medical_treatmentAlveolar Bone LossFibrin matrixDentistrylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawPlatelet-Rich FibrinmedicineHumansPeriodontologyPeriodontitisFlap SurgeryGeneral DentistryTitaniumGuided Tissue Regenerationbusiness.industryResearchSignificant differenceOpen flap debridementIntrabony DefectsAttachment level030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Platelet-rich fibrindigestive system diseasesRoot Canal TherapyTreatment OutcomeDebridementOtorhinolaryngologyDebridement (dental)UNESCO::CIENCIAS MÉDICASGuided Tissue Regeneration PeriodontalSurgerybusiness
researchProduct